Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that the Company will be presenting at the annual meeting of the International Society of Cell and Gene Therapy (ISCT) taking place on May 26-28, 2021.
Organicell’s work, which was selected for an oral presentation, will be part of a session titled: “EVs for Infectious Diseases and Preparedness for Future Pandemics - ISCT-ISEV Joint Session” and is scheduled to be broadcast live to program registrants on May 27th.
This presentation comes as a follow up to recently published case report studies demonstrating the investigation of Zofin™ in three severely ill COVID-19 patients. In these studies, results found the administration of Zofin™ to be associated with decreased levels of inflammatory biomarkers, such as CRP and IL6.
COVID-19 infection complications are, in part, the result of an excessive immune response with the over-production of pro-inflammatory cytokines such as IL6 and CRP. Therefore, the observation of reduced concentration of these biomarkers may indicate a positive trend towar...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).